TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
What’s Going to Be Big at TCT 2024? | tctmd.com
Oct 17, 2024 · TCT 2024, the annual scientific showcase of interventional cardiovascular medicine, is returning once again to Washington, DC. The 4-day meeting starts Sunday, October 27, 2024, and will involve more than 1,400 faculty spread out across 161 different sessions, including 33 live endovascular, structural, and coronary cases. Three sessions, one per day, will deliver 11 late-breaking clinical ...
PCR London Valves 2024 | tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Coronary CTA Reimbursement for US Hospitals to Double in 2025
Nov 8, 2024 · For once, cardiologists find good news in the US Centers for Medicare & Medicaid Services (CMS) annual Hospital Outpatient Prospective Payment System (HOPPS) final rule: in 2025 the payment rate for coronary computed tomography angiography (CCTA) will double.
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial …
Oct 29, 2024 · WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients treated with PCI after acute myocardial infarction, results from the CLEAR SYNERGY (OASIS 9) trial show.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR …
Nov 18, 2024 · CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with the therapies reducing Lp(a) by roughly 80% over extended follow-up.
TCTMD Login - tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
EARLY TAVR Breaks New Ground for Preemptive Treatment of …
Oct 28, 2024 · Disclosures. EARLY TAVR was sponsored by Edwards Lifesciences. Généreux reports consulting for and/or receiving speaking fees from Abbott Vascular, Abiomed, Boston Scientific, Caranx Medical, Cardiovascular System Inc, Edwards Lifesciences, GE Healthcare, iRhythm Technologies, Medtronic, OpSens, Pi-Cardiac, Puzzle Medical, Saranas, Shockwave, Siemens, Soundbite Medical Inc, Teleflex, and 4C ...